| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 29, 2025 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 29, 2025 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - BNB PLUS CORP. (0000744452) (Issuer)
3 - BNB PLUS CORP. (0000744452) (Issuer)
4 - BNB PLUS CORP. (0000744452) (Issuer)
Patent Covers the Composition of LineaRx's Proprietary Linea™ RNA Polymerase (RNAP), a Core Technology Empowering the Linea™ IVT Platform BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis." The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (RNAP) enzyme branded Linea RNAP. The Company plans to validate the patent in key Europ
Provides Updated on BNB Token Holdings and Operating Company Performance BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment of both orders is expected to be completed prior to June 2026. "We're pleased to receive these new orders from leading genetic medicine companies," said Clay Shorrock, President and CEO of BNBX. "We believe our continued engagements with top-tier customers demonstrates both the technical excellence of our LineaDNA platform and our continued operational execution.
Digital Asset and Infrastructure Expert Joins Board to Support Strategic Growth and BNB Treasury Operations BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Committee, effective as of February 2, 2026. Mr. Haft is a recognized pioneer in digital asset investments and decentralized finance, bringing more than 35 years of experience spanning blockchain infrastructure, emerging markets, and traditional finance. Mr. Haft has served as a managing director at Bear Stearns Inc, Furman Selz and ING Barings, where he focused on emerging markets, and founded and served as chairman
PRE 14A - BNB PLUS CORP. (0000744452) (Filer)
SCHEDULE 13G - BNB PLUS CORP. (0000744452) (Subject)
10-Q - BNB PLUS CORP. (0000744452) (Filer)
Digital Asset and Infrastructure Expert Joins Board to Support Strategic Growth and BNB Treasury Operations BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Committee, effective as of February 2, 2026. Mr. Haft is a recognized pioneer in digital asset investments and decentralized finance, bringing more than 35 years of experience spanning blockchain infrastructure, emerging markets, and traditional finance. Mr. Haft has served as a managing director at Bear Stearns Inc, Furman Selz and ING Barings, where he focused on emerging markets, and founded and served as chairman
Rebrand Aligned with Yield-Focused BNB Treasury and BNBX Ticker Appointment Strengthens DeFi Leadership Applied DNA Sciences, Inc. (NASDAQ:BNBX) (the "Company") today announced that it will change its name to BNB Plus Corp. ("BNB Plus"), reflecting the Company's commitment to delivering a yield-optimized, BNB-based digital asset treasury strategy leveraging the Binance ecosystem. Alongside the rebrand, the Company also announced the appointment of Josh Kruger as Chairman of the Board. Mr. Kruger has deep expertise in managing blockchain-native assets for yield and capital efficiency. He is the founder of OnChain Alpha and previously served as Head of Trading at Coral Capital, which wa
Company Acquires 3,349 Additional BNB Tokens LineaRx Subsidiary Expected to Narrow Losses and Approach Profitability in FY26Q1 Company Launches New Corporate Website and Branding BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing of losses at its LineaRx, Inc. ("LineaRx") subsidiary, and the launch of a new corporate website and branding. Significant Addition to BNB Treasury The Company has opportunistically deployed an additional approximately $3 million to acquire additional BNB tokens at an average price of approximately $895 per token, further strengthening the C
Company Launches BNBX.io to Provide Robust Real-Time Portfolio and Company Metrics Company Recently Closed Up to $58 Million Private Placement to Launch Yield-Focused BNB Treasury Applied DNA Sciences, Inc. (NASDAQ:BNBX) ( "BNBX" or the "Company") today announced the launch of BNBX.io, which provides real-time portfolio metrics updating the market on the Company's BNB treasury holdings, key valuation metrics, and detailed information about the capitalization structure of the Company (the "Dashboard"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028565774/en/ "The launch of our Dashboard reflects BNBX's commitment to re
Company Officially Launches Yield-Focused Digital Asset Treasury Strategy Streamlines Operations, Achieving Approximately $2.9 Million in Annualized Cost Savings Applied DNA Sciences, Inc. (NASDAQ:BNBX) ("Applied DNA", "BNBX" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced the successful close of its previously announced private investment in public equity ("PIPE") financing led by institutional DeFi and TradFi investors. The PIPE resulted in gross proceeds of approximately $27 Million to the Company, before deducting placement agent fees and other offering e